|
The pharmaceutical industry is currently experiencing a crisis in the identification of novel compounds that successfully make their way through clinical drug development to regulatory approval.
Fragment-based drug discovery (FBDD) was introduced a decade ago and is a promising method of identifying high-quality lead compounds.
|
